Announcement • May 28
ISEC Healthcare Ltd. Approves Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2025 ISEC Healthcare Ltd. at its AGM held on April 29, 2026, approved a final tax exempt (one-tier) dividend of 0.58 Singapore cents per ordinary share for the financial year ended 31 December 2025. Reported Earnings • Apr 17
Full year 2025 earnings released: EPS: S$0.023 (vs S$0.022 in FY 2024) Full year 2025 results: EPS: S$0.023 (up from S$0.022 in FY 2024). Revenue: S$79.2m (up 6.8% from FY 2024). Net income: S$13.4m (up 4.2% from FY 2024). Profit margin: 17% (in line with FY 2024). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year. Reported Earnings • Mar 04
Full year 2025 earnings released: EPS: S$0.023 (vs S$0.022 in FY 2024) Full year 2025 results: EPS: S$0.023 (up from S$0.022 in FY 2024). Revenue: S$79.2m (up 6.8% from FY 2024). Net income: S$13.4m (up 4.2% from FY 2024). Profit margin: 17% (in line with FY 2024). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year. Declared Dividend • Mar 02
Dividend reduced to S$0.0058 Dividend of S$0.0058 is 17% lower than last year. Ex-date: 11th May 2026 Payment date: 26th May 2026 Dividend yield will be 1.7%, which is lower than the industry average of 3.1%. Announcement • Feb 27
ISEC Healthcare Ltd., Annual General Meeting, Apr 29, 2026 ISEC Healthcare Ltd., Annual General Meeting, Apr 29, 2026. Announcement • Nov 28
ISEC Healthcare Ltd. Announces Change in Company Secretaries, Effective 1 December 2025 The Board of Directors (the "Board") of ISEC Healthcare Ltd. announced the appointment of Mr. Yoo Loo Ping and Ms. Cheng Lisa as the Company Secretaries of the Company in place of Ms. Ngiam May Ling ("Ms. Ngiam") with effect from 1 December 2025. Reported Earnings • Oct 24
Third quarter 2025 earnings released: EPS: S$0.007 (vs S$0.007 in 3Q 2024) Third quarter 2025 results: EPS: S$0.007 (in line with 3Q 2024). Revenue: S$20.7m (up 8.7% from 3Q 2024). Net income: S$3.91m (down 8.5% from 3Q 2024). Profit margin: 19% (down from 23% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Aug 14
Second quarter 2025 earnings released: EPS: S$0.007 (vs S$0.006 in 2Q 2024) Second quarter 2025 results: EPS: S$0.007 (up from S$0.006 in 2Q 2024). Revenue: S$20.0m (up 8.2% from 2Q 2024). Net income: S$3.72m (up 9.4% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 6% per year. Reported Earnings • Apr 23
First quarter 2025 earnings released First quarter 2025 results: EPS: S$0.005. Revenue: S$17.9m (up 5.6% from 1Q 2024). Net income: S$3.09m (down 2.5% from 1Q 2024). Profit margin: 17% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Announcement • Apr 03
ISEC Healthcare Ltd., Annual General Meeting, Apr 21, 2025 ISEC Healthcare Ltd., Annual General Meeting, Apr 21, 2025, at 10:00 Singapore Standard Time. Location: relc international hotel, 30 orange grove road, singapore 258352, Singapore Buy Or Sell Opportunity • Mar 07
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to S$0.32. The fair value is estimated to be S$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 15%. Declared Dividend • Mar 02
Final dividend reduced to S$0.007 Dividend of S$0.007 is 18% lower than last year. Ex-date: 28th April 2025 Payment date: 9th May 2025 Dividend yield will be 2.8%, which is lower than the industry average of 3.1%. Sustainability & Growth Dividend is covered by earnings (48% earnings payout ratio) but not covered by cash flows (119% cash payout ratio). The dividend has increased by an average of 26% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.5% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 28
Full year 2024 earnings released: EPS: S$0.022 (vs S$0.023 in FY 2023) Full year 2024 results: EPS: S$0.022 (down from S$0.023 in FY 2023). Revenue: S$74.2m (up 6.0% from FY 2023). Net income: S$12.8m (down 1.1% from FY 2023). Profit margin: 17% (down from 19% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 24
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: S$19.0m (up 5.0% from 3Q 2023). Net income: S$4.27m (up 13% from 3Q 2023). Profit margin: 23% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. Declared Dividend • Aug 15
First half dividend reduced to S$0.003 Dividend of S$0.003 is 61% lower than last year. Ex-date: 19th August 2024 Payment date: 29th August 2024 Dividend yield will be 3.1%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (88% cash payout ratio). The dividend has increased by an average of 35% per year over the past 9 years. However, payments have been volatile during that time. Earnings per share has grown by 10% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: S$0.006 (vs S$0.005 in 2Q 2023) Second quarter 2024 results: EPS: S$0.006 (up from S$0.005 in 2Q 2023). Revenue: S$18.5m (up 5.6% from 2Q 2023). Net income: S$3.40m (up 22% from 2Q 2023). Profit margin: 18% (up from 16% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Apr 30
ISEC Healthcare Ltd. Appoints Wee Kim Lin Evelyn as Non-Executive and Independent Director, Effective May 1, 2024 ISEC Healthcare Ltd. announced the appointment of Wee Kim Lin Evelyn as Non-Executive and Independent Director Member of Audit Committee, Chairman of Nominating Committee, Chairman of Remuneration Committee, effective May 1, 2024. Working Experience: Sep 2007 - Present Partner, Rajah & Tann Singapore LLP. Other DirectorShips Present: Director, R & T Corporate Services Pte. Ltd. Partner, Rajah & Tann Singapore LLP. Professional Qualifications: Advocate & Solicitor, Supreme Court Of Singapore ii. Bachelor Of Laws (Honours) (LLB), National University of Singapore iii. Solicitor, England & Wales (Non-Practising), Solicitors Regulation Authority iv. Accredited Mediator, Singapore Mediation Centre v. Accredited Mediator, Singapore International Mediation Institute. Declared Dividend • Apr 24
Dividend reduced to S$0.0085 Dividend of S$0.0085 is 21% lower than last year. Ex-date: 26th April 2024 Payment date: 9th May 2024 Dividend yield will be 4.2%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is covered by both earnings (71% earnings payout ratio) and cash flows (89% cash payout ratio). The dividend has increased by an average of 35% per year over the past 9 years. However, payments have been volatile during that time. Earnings per share has grown by 6.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 21
First quarter 2024 earnings released First quarter 2024 results: EPS: S$0.006. Revenue: S$16.9m (flat on 1Q 2023). Net income: S$3.17m (down 5.7% from 1Q 2023). Profit margin: 19% (down from 20% in 1Q 2023). Announcement • Mar 28
ISEC Healthcare Ltd., Annual General Meeting, Apr 19, 2024 ISEC Healthcare Ltd., Annual General Meeting, Apr 19, 2024, at 10:00 Singapore Standard Time. Location: Hotel Royal, 36 Newton Road, Singapore 307964, Singapore Singapore Agenda: To Adoption of Directors' Statement and Audited Financial Statements for the financial year ended 31 December 2023 together with the Independent Auditor's Report thereon; to discuss Declaration of a final tax exempt (one-tier) dividend; to Re-election of Dr Lee Hung Ming as a Director of the Company; to Approval of Directors' fees; to re-appoint Mazars LLP as the Independent Auditors of the Company; to discuss Authority to allot and issue shares; to discuss Authority to issue shares under the ISEC Healthcare Performance Share Plan; and to discuss Proposed Renewal of the Share Buyback Mandate. Buy Or Sell Opportunity • Mar 20
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to S$0.41. The fair value is estimated to be S$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 29%. Reported Earnings • Feb 23
Full year 2023 earnings released: EPS: S$0.023 (vs S$0.022 in FY 2022) Full year 2023 results: EPS: S$0.023 (up from S$0.022 in FY 2022). Revenue: S$70.0m (up 11% from FY 2022). Net income: S$13.0m (up 3.5% from FY 2022). Profit margin: 19% (down from 20% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 21
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: S$18.1m (up 2.5% from 3Q 2022). Net income: S$3.79m (up 4.8% from 3Q 2022). Profit margin: 21% (in line with 3Q 2022). Announcement • Oct 21
ISEC Healthcare Ltd. Reports Property, Plant and Equipment Written-Off for the Third Quarter Ended September 30, 2023 ISEC Healthcare Ltd. reported Property, plant and equipment written-off for the third quarter ended September 30, 2023. For the quarter, the company's property, plant and equipment written-off was SGD 7,000 against SGD 1,000 a year ago. Buying Opportunity • Oct 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be S$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 35%. Buying Opportunity • Sep 21
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 6.9%. The fair value is estimated to be S$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 35%. Buying Opportunity • Aug 21
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 6.9%. The fair value is estimated to be S$0.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 35%. Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: S$0.005 (vs S$0.006 in 2Q 2022) Second quarter 2023 results: EPS: S$0.005 (down from S$0.006 in 2Q 2022). Revenue: S$17.5m (up 8.2% from 2Q 2022). Net income: S$2.77m (down 13% from 2Q 2022). Profit margin: 16% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 07
Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021) Full year 2022 results: EPS: S$0.022 (up from S$0.013 in FY 2021). Revenue: S$63.0m (up 56% from FY 2021). Net income: S$12.5m (up 81% from FY 2021). Profit margin: 20% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 23
Full year 2022 earnings released: EPS: S$0.022 (vs S$0.013 in FY 2021) Full year 2022 results: EPS: S$0.022 (up from S$0.013 in FY 2021). Revenue: S$63.0m (up 56% from FY 2021). Net income: S$12.5m (up 81% from FY 2021). Profit margin: 20% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Oct 22
ISEC Healthcare Ltd. Reports Write Offs for the Quarter Ended September 30, 2022 ISEC Healthcare Ltd. reported write offs for the quarter ended September 30, 2022. for the quarter, the company reported Property, plant and equipment written-off of SGD 1,000. Reported Earnings • Oct 22
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: S$17.7m (up 115% from 3Q 2021). Net income: S$3.62m (up 201% from 3Q 2021). Profit margin: 21% (up from 15% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 01
ISEC Healthcare Ltd. Appoints Shin Hoy Choong as Medical Director ISEC Healthcare Ltd. announced the appointment of Dr. Shin Hoy Choong as Medical director. Date of appointment is September 1, 2022. Reported Earnings • Aug 14
Second quarter 2022 earnings released: EPS: S$0.006 (vs S$0.003 in 2Q 2021) Second quarter 2022 results: EPS: S$0.006 (up from S$0.003 in 2Q 2021). Revenue: S$16.1m (up 62% from 2Q 2021). Net income: S$3.18m (up 81% from 2Q 2021). Profit margin: 20% (up from 18% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 1% per year. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues in line with analyst expectations First quarter 2022 results: Revenue: S$11.8m (up 30% from 1Q 2021). Net income: S$2.30m (up 64% from 1Q 2021). Profit margin: 20% (up from 16% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Apr 23
ISEC Healthcare Ltd. Approves Declaration of Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended December 31, 2021 ISEC Healthcare Ltd. approve declaration of final tax exempt (one-tier) dividend of 0.30 Singapore cents per ordinary share for the financial year ended December 31, 2021, at the annual general meeting held on April 22, 2022. Announcement • Feb 25
ISEC Healthcare Ltd. Proposes Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended December 31, 2021, Payable on 11 May 2022 ISEC Healthcare Ltd. proposed a final tax exempt (one-tier) dividend of 0.30 Singapore cents per ordinary share for the financial year ended December 31, 2021. The proposed final dividend is subject to the approval of shareholders at the forthcoming annual general meeting of the Company ("AGM"). The dividends will be paid on 11 May 2022 if approved by shareholders. Buying Opportunity • Feb 04
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be S$0.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.3% per annum over the last 3 years. Earnings per share has declined by 18% per annum over the last 3 years. Reported Earnings • Oct 23
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: S$8.20m (down 27% from 3Q 2020). Net income: S$1.20m (down 53% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Executive Departure • Apr 27
Non-Executive Independent Chairman Yih Pin Sitoh has left the company On the 21st of April, Yih Pin Sitoh's tenure as Non-Executive Independent Chairman ended after 6.6 years in the role. We don't have any record of a personal shareholding under Yih Pin's name. A total of 2 executives have left over the last 12 months. Reported Earnings • Apr 10
Full year 2020 earnings released: EPS S$0.009 (vs S$0.014 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: S$36.3m (down 15% from FY 2019). Net income: S$4.69m (down 37% from FY 2019). Profit margin: 13% (down from 17% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Reported Earnings • Feb 26
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: S$36.3m (down 15% from FY 2019). Net income: S$4.69m (down 37% from FY 2019). Profit margin: 13% (down from 17% in FY 2019). The decrease in margin was driven by lower revenue. Announcement • Feb 25
ISEC Healthcare Ltd., Annual General Meeting, Apr 21, 2021 ISEC Healthcare Ltd., Annual General Meeting, Apr 21, 2021. Agenda: To propose final tax exempt (one-tier) dividend in respect of the financial year ended 31 December 2020. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of S$5.56m, down 25% from the prior year. Total revenue was S$37.8m over the last 12 months, down 9.4% from the prior year.